Peter Fromen Net Worth

The estimated Net Worth of Peter Fromen is at least $518 Mille dollars as of 11 January 2022. Peter Fromen owns over 19,720 units of Pacific Biosciences of California Inc stock worth over $235,670 and over the last 4 years Peter sold PACB stock worth over $281,996.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Peter Fromen PACB stock SEC Form 4 insiders trading

Peter has made over 1 trades of the Pacific Biosciences of California Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently Peter sold 19,720 units of PACB stock worth $281,996 on 11 January 2022.

The largest trade Peter's ever made was selling 19,720 units of Pacific Biosciences of California Inc stock on 11 January 2022 worth over $281,996. On average, Peter trades about 6,573 units every 0 days since 2021. As of 11 January 2022 Peter still owns at least 140,280 units of Pacific Biosciences of California Inc stock.

You can see the complete history of Peter Fromen stock trades at the bottom of the page.

What's Peter Fromen's mailing address?

Peter's mailing address filed with the SEC is PACIFIC BIOSCIENCES OF CALIFORNIA, INC.,, 1305 O'BRIEN DRIVE, MENLO PARK, CA, 94025.

Insiders trading at Pacific Biosciences of California Inc

Over the last 14 years, insiders at Pacific Biosciences of California Inc have traded over $95,441,111 worth of Pacific Biosciences of California Inc stock and bought 2,252,330 units worth $6,097,136 . The most active insiders traders include Michael Hunkapiller, John F Milligan e Christian O Henry. On average, Pacific Biosciences of California Inc executives and independent directors trade stock every 44 days with the average trade being worth of $202,112. The most recent stock trade was executed by Jeff Eidel on 19 August 2024, trading 26,760 units of PACB stock currently worth $42,548.

What does Pacific Biosciences of California Inc do?

pacbio develops comprehensive solutions for scientists that propel the field of genomics, improve science and research, and create positive impact globally. we provide sophisticated genomic analysis systems that deliver invaluable insights for scientists who strive to resolve complex genetic challenges. our strength comes from the dedication of our people, who are fueled by a desire to effect real, positive change. with a focus on the future and an experienced, passionate team, we are motivated to continue to redefine what is possible in genomics.

Complete history of Peter Fromen stock trades at Pacific Biosciences of California Inc

Pacific Biosciences of California Inc executives and stock owners

Pacific Biosciences of California Inc executives and other stock owners filed with the SEC include:

• Michael Hunkapiller,
  Director
• Christian O. Henry M.B.A.,
  Pres, CEO & Director
• Susan G. Kim,
  Chief Financial Officer
• Dr. Denis Zaccarin Ph.D.,
  Sr. VP of R&D
• William Ericson,
  Independent Director
• Randall Livingston,
  Independent Director
• Marshall Mohr,
  Independent Director
• John Milligan,
  Independent Chairman of the Board
• Lucy Shapiro,
  Independent Director
• Kathy Ordonez,
  Director
• Christian Henry,
  President, Chief Executive Officer, Director
• David Botstein,
  Independent Director
• Susan Kim,
  Chief Principal Officer, Chief Accounting Officer
• Eric Schaefer,
  Chief Accounting Officer, Vice President
• Denis Zaccarin,
  Vice President - Semiconductor Integration Devices
• Chris Seipert,
  Vice President, Sales, Service & Support, EMEA and America
• Kathleen Lynch J.D.,
  Head of Global Gov. Affairs & Corp. Communications
• Michele Farmer CPA,
  VP & Chief Accounting Officer
• Kathleen Lynch,
  Head of Global Gov. Affairs & Corp. Communications
• Brett Atkins J.D., Ph.D.,
  Gen. Counsel & Corp. Sec.
• Trevin Rard,
  Head of Investor Relations
• Dr. Jonas Korlach Ph.D.,
  Chief Scientific Officer
• Michele Farmer,
  VP & Chief Accounting Officer
• Mark Van Oene,
  Chief Operating Officer
• Dr. Stephen Turner,
  Co-Founder & CTO
• James Michael Phillips,
  SVP, Research & Development
• Susan K Barnes,
  EVP, CFO and PAO
• Kevin P Corcoran,
  SVP, Market Development
• Brook H Byers,
  Director
• Jeff Eidel,
  See Remarks
• Brian B Dow,
  VP and PAO
• Michael Glynn,
  Chief Commercial Officer
• David B Singer,
  Director
• Susan E Siegel,
  Director
• Hugh C Martin,
  Chairman, CEO & President
• Stephen W Turner,
  VP & Chief Technology Officer
• Hannah Valantine,
  Director
• Oene Mark Van,
  See Remarks
• Peter Fromen,
  See Remarks
• Michele Farmer,
  See Remarks
• David W Meline,
  Director